目的 探討骨疏康膠囊聯(lián)合利塞膦酸鈉治療絕經(jīng)后骨質(zhì)疏松癥的臨床療效。方法 選取2019年1月—2020年1月在河南理工大學(xué)第一附屬醫(yī)院（焦作市第二人民醫(yī)院）進行診治的114例絕經(jīng)后骨質(zhì)疏松癥患者為研究對象，根據(jù)就診順序隨機分為對照組（57例）和治療組（57例）。對照組餐前30 min直立位口服利塞膦酸鈉片，5 mg/次，1次/d。治療組在對照組基礎(chǔ)上口服骨疏康膠囊，4粒/次，2次/d。兩組均經(jīng)過6個月治療。觀察兩組的臨床療效，比較兩組治療前后相關(guān)評分、骨密度和骨代謝指標的變化情況。結(jié)果 經(jīng)治療，治療組總有效率96.49%，顯著高于對照組的84.20%（P<0.05）。經(jīng)治療，兩組VAS評分顯著降低，而SF-36評分顯著升高（P<0.05）；治療后，治療組VAS評分低于對照組，而SF-36評分高于對照組（P<0.05）。經(jīng)治療，兩組L2～4及股骨頸骨密度均較治療前顯著增加（P<0.05）；治療后，治療組骨密度高于對照組（P<0.05）。經(jīng)治療，兩組血清骨鈣素（BGP）、抗酒石酸酸性磷酸酶（TRACP-5b）、骨保護素（OPG）、β-膠原降解產(chǎn)物（β-CTX）水平均較治療前顯著降低，但骨堿性磷酸酶（B-ALP）、I型前膠原氨基端原肽（PINP）顯著升高（P<0.05）；且治療后，治療組這些骨代謝指標顯著優(yōu)于對照組（P<0.05）。結(jié)論 骨疏康膠囊聯(lián)合利塞膦酸鈉治療絕經(jīng)后骨質(zhì)疏松癥具有較好的臨床療效，可顯著改善患者臨床癥狀，抑制骨吸收、促進骨形成，提高骨密度及患者生活質(zhì)量，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the effect of Gushukang Capsules combined with risedronate sodium in treatment of postmenopausal osteoporosis. Methods 114 Cases of postmenopausal osteoporosis patients diagnosed and treated in the First Affiliated Hospital of Henan Polytechnic University (Jiaozuo Second People's Hospital) from January 2019 to January 2020 were selected as research objects, and randomly divided into control group (57 cases) and treatment group (57 cases) according to the order of treatment. The control group po administered with Risedronate Sodium Tablets at an upright position 30 min before meal, 5 mg/time, once daily. Patients in the treatment group were po administered with Gushukang Capsules on the basis of the control group, 4 grains/time, twice daily. Patients in two groups were treated for 6 months. The clinical efficacy of the two groups was observed, and the changes of relevant scores, bone mineral density and bone metabolism indexes before and after treatment were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 96.49%, significantly higher than that of the control group (84.20%, P<0.05). After treatment, VAS score was significantly decreased in both groups, while SF-36 score was significantly increased (P<0.05). After treatment, VAS score in the treatment group was lower than that in the control group, while SF-36 score was higher than that in the control group (P<0.05). After treatment, the BMD of L2-4 and femoral neck in both groups was significantly higher than that before treatment (P<0.05). After treatment, bone mineral density in the treatment group was higher than that in the control group (P<0.05). After treatment, the serum levels of BGP, TRACP-5b, OPG, β-CTX in both groups were significantly lower than those before treatment, but B-ALP and PINP were significantly higher (P<0.05). After treatment, these bone metabolism indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Gushukang Capsules combined with risedronate sodium has good clinical effect in treatment of postmenopausal osteoporosis, and can significantly improve patients' clinical symptoms, inhibit bone absorption, and also can promote bone formation, improve bone density and patients' life quality, which has certain clinical application value.

R977

河南省醫(yī)學(xué)科技攻關(guān)計劃聯(lián)合共建項目（LHGJ20191356）